Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data

June 15, 2026 11:23 AM EDT News Briefing Gan & Lee's Phase 3 obe­si­ty suc­cess­es; J&J touts mul­ti­ple myelo­ma da­ta ENDPOINTS Plus news about Sanofi, Phar­ma­Mar, Jazz, Rhythm Phar­ma­ceu­ti­cals, Spyre and Zymeworks 🇨🇳 An­oth­er obe­si­ty read­out from Chi­na: Gan & Lee Phar­ma­ceu­ti­cals, a Chi­na-based in­sulin spe­cial­ist … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER